Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim…
<!-- Name:DistributionId Value:8799355 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
COURAGEALS
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing…
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of COURAGE-ALS OLE (Clinical Outcomes Using Reldesemtiv…